Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GlucoTrack, Inc. - Common Stock (NQ:GCTK)

0.2274 +0.0529 (+30.32%)
Streaming Delayed Price Updated: 3:45 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GlucoTrack, Inc. - Common Stock

Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care
Via TheNewswire.com
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial
By JE Insights, Benzinga 
Via TheNewswire.com
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
The study met its primary endpoint with no procedure or device related serious adverse events reported 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack Announces Reverse Stock Split
1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack Announces ISO 13485:2016 Certification
ISO Certification highlights commitment to quality for continuous blood glucose monitor 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack to Present at TechBio Showcase™ 2025
Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes 
From Glucotrack, Inc.
Via GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with GlucoTrack and Acceleware Discussing Their Latest News
Via ACCESSWIRE
Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)
Via ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with NextSource, Good Natured Products, SoLVBL, Geologica and GlucoTrack Discussing Their Latest News
Via ACCESSWIRE
GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK
From GlucoTrack, Inc.
Via GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with SoLVBL, C3 Metals, Charbone Hydrogen, GlucoTrack and Atomic Minerals Discussing Their Latest News
Via ACCESSWIRE
GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEM
From GlucoTrack, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.